A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Dec 2016
At a glance
- Drugs TM 601 I-131 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors TransMolecular
- 22 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Sep 2008 New source of information identified (Transmolecular media release).
- 30 Sep 2008 TM 601 I-131 dosing initiated according to a Transmolecular media release.